FOLH1 and Familial prostate cancer: Kranzbühler et al. treated LNCaP prostate cancer cells and PNT1A epithelial prostate cells with enzalutamide, dutasteride, rapamycin, metformin, Lovastatin, and acetylsalicylic acid and assessed its impact on PSMA and AR expression using flow cytometry, immunohistochemistry, and immunoblotting.